Mereo BioPharma Group plc
MREOAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Dec 30, 2025 | Jefferies | Maury Raycroft | $0.50(+75%) | $0.29 | StreetInsider |
| Dec 29, 2025 | Robert W. Baird | $1.00(+256%) | $0.28 | TheFly | |
| Dec 29, 2025 | BTIG | $1.00(+259%) | $0.28 | TheFly | |
| Dec 18, 2025 | BTIG | Julian Harrison | $6.00(+213%) | $1.92 | StreetInsider |
| Jul 10, 2025 | Needham | Gil Blum | $5.00(+168%) | $1.86 | TheFly |
| Jun 20, 2024 | Leerink Partners | Joseph Schwartz | $8.00(+101%) | $3.98 | TheFly |
| Jun 12, 2024 | Robert W. Baird | Jack Allen | $8.00(+109%) | $3.83 | StreetInsider |
| Jun 12, 2024 | Needham | Gil Blum | $7.00(+99%) | $3.52 | StreetInsider |
| Mar 28, 2024 | Needham | Gil Blum | $6.00(+100%) | $3.00 | StreetInsider |
| Aug 12, 2022 | Cantor Fitzgerald | $4.00(+196%) | $1.35 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| JP Morgan | downgrade | Neutral →Underweight | Aug 19, 2026 |
| Needham | maintain | Buy | Aug 11, 2026 |
| BTIG | maintain | Buy | Aug 11, 2026 |
| BTIG | maintain | Buy | May 12, 2026 |
| JP Morgan | downgrade | Overweight →Neutral | Mar 23, 2026 |
| BTIG | maintain | Buy | Jan 16, 2026 |
| Needham | maintain | Buy | Jan 13, 2026 |
| Jefferies | downgrade | Buy →Hold | Dec 30, 2025 |
| BTIG | maintain | Buy | Dec 29, 2025 |
| LifeSci Capital | downgrade | Outperform →Market Perform | Dec 29, 2025 |
| Needham | maintain | Buy | Dec 22, 2025 |
| BTIG | maintain | Buy | Dec 18, 2025 |
| JP Morgan | maintain | Overweight | Aug 25, 2025 |
| Needham | maintain | Buy | Jul 10, 2025 |
| Needham | maintain | Buy | May 13, 2025 |
| Needham | maintain | Buy | Apr 9, 2025 |
| Needham | maintain | Buy | Mar 26, 2025 |
| Cantor Fitzgerald | maintain | Overweight | Mar 18, 2025 |
| Needham | maintain | Buy | Jan 13, 2025 |
| Needham | maintain | Buy | Dec 17, 2024 |
| Needham | maintain | Buy | Nov 12, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Oct 1, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Sep 16, 2024 |
| Needham | maintain | Buy | Aug 13, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Jul 22, 2024 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-0.01 | $-0.01 | — | $3.5M |
| May 12, 2026 | $-0.01 | $0.02 | — | $11.7M |
| Mar 19, 2026 | $-0.01 | $-0.01 | — | $23.3M |
| Nov 10, 2025 | $-0.01 | $-0.01 | $300.0K | $5.3M |
| Aug 12, 2025 | $-0.02 | $-0.01 | $685.7K | — |
| May 13, 2025 | $-0.02 | $-0.01 | — | $11.9M |
| Mar 26, 2025 | $-0.01 | $-0.02 | $1.3M | $11.9M |
| Nov 12, 2024 | $-7.69 | $-1.36 | — | — |
News
Mereo BioPharma Group plc - Sponsored ADR (NASDAQ: MREO - Get Free Report) has earned a consensus recommendation of "Hold" from the eight ratings firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy
Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo's investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026 Cash and cash equivalents of $30.1 million at June 30, 2026, now expected to fund operations into late-2027 LONDON, Aug. 11, 2026 (…
Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory disease On option exercise, Sentynl will have the right to commercialize the product in the United States; Mereo to lead global development and retains rest of the world rights Mereo will receive an upfront option fee and, on option exercise, is eligible to receive up to $40 million in upfront and R&D payments until NDA filing, and double-digit tiered royalties on U.S. …